K Ray Chaudhuri1, P Martinez-Martin. 1. National Parkinson Foundation Centre of Excellence, King's College Hospital, University Hospital Lewisham, Kings College and Institute of Psychiatry, London, UK. Ray.Chaudhuri@uhl.nhs.uk
Abstract
BACKGROUND: Disabling non-motor symptoms (NMS) associated with Parkinson's disease (PD), such as dementia and loss of balance, do not respond well to levodopa therapy and can lead to eventual death in patients with the disease. In 2006, a multidisciplinary group of experts and patient representatives developed an NMS screening questionnaire (NMSQuest) and a unified Non-Motor Symptoms Scale (NMSS) to address the need for simple identification and comprehensive assessment of NMS in patients with PD. METHODS AND RESULTS: An international pilot study of 96 healthy controls and 123 patients with various stages of treated and untreated PD was conducted to demonstrate that the NMSQuest is a feasible, valid, and accepted tool. CONCLUSION: The majority of patients and caregivers felt that the questionnaire was clear and relevant to their daily lives. Data from 242 PD patients with no dementia were analysed in a pilot study on the clinimetric validation of NMSS. Similar to the NMSQuest study, the NMSS study revealed a significant correlation between progression of PD and increasing NMS burden. These studies suggest that the NMSQuest accurately detects the NMS, and that the NMSS closely correlates with quality of life for PD patients.
BACKGROUND: Disabling non-motor symptoms (NMS) associated with Parkinson's disease (PD), such as dementia and loss of balance, do not respond well to levodopa therapy and can lead to eventual death in patients with the disease. In 2006, a multidisciplinary group of experts and patient representatives developed an NMS screening questionnaire (NMSQuest) and a unified Non-Motor Symptoms Scale (NMSS) to address the need for simple identification and comprehensive assessment of NMS in patients with PD. METHODS AND RESULTS: An international pilot study of 96 healthy controls and 123 patients with various stages of treated and untreated PD was conducted to demonstrate that the NMSQuest is a feasible, valid, and accepted tool. CONCLUSION: The majority of patients and caregivers felt that the questionnaire was clear and relevant to their daily lives. Data from 242 PDpatients with no dementia were analysed in a pilot study on the clinimetric validation of NMSS. Similar to the NMSQuest study, the NMSS study revealed a significant correlation between progression of PD and increasing NMS burden. These studies suggest that the NMSQuest accurately detects the NMS, and that the NMSS closely correlates with quality of life for PDpatients.
Authors: Caroline A Mulvaney; Gonçalo S Duarte; Joel Handley; David Jw Evans; Suresh Menon; Richard Wyse; Hedley Ca Emsley Journal: Cochrane Database Syst Rev Date: 2020-07-23
Authors: Anas Arab; Jana Ruda-Kucerova; Alzbeta Minsterova; Eva Drazanova; Nikoletta Szabó; Zenon Starcuk; Irena Rektorova; Amit Khairnar Journal: Neurotox Res Date: 2019-06-18 Impact factor: 3.911
Authors: Ariel B Neikrug; Jeanne E Maglione; Lianqi Liu; Loki Natarajan; Julie A Avanzino; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel Journal: J Clin Sleep Med Date: 2013-11-15 Impact factor: 4.062
Authors: Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk Journal: PLoS One Date: 2010-01-19 Impact factor: 3.240